Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

65 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Glycosylated nanoparticle-based PfCSP vaccine confers long-lasting antibody responses and sterile protection in mouse malaria model.
Ludwig J, Scally SW, Costa G, Hoffmann S, Murugan R, Lossin J, Prieto K, Obraztsova A, Lobeto N, Franke-Fayard B, Janse CJ, Lebas C, Collin N, Binter S, Kellam P, Levashina EA, Wardemann H, Julien JP. Ludwig J, et al. Among authors: collin n. NPJ Vaccines. 2023 Apr 7;8(1):52. doi: 10.1038/s41541-023-00653-7. NPJ Vaccines. 2023. PMID: 37029167 Free PMC article.
Author Correction: Glycosylated nanoparticle-based PfCSP vaccine confers long-lasting antibody responses and sterile protection in mouse malaria model.
Ludwig J, Scally SW, Costa G, Hoffmann S, Murugan R, Lossin J, Prieto K, Obraztsova A, Lobeto N, Franke-Fayard B, Janse CJ, Lebas C, Collin N, Binter S, Kellam P, Levashina EA, Wardemann H, Julien JP. Ludwig J, et al. Among authors: collin n. NPJ Vaccines. 2023 Jun 5;8(1):86. doi: 10.1038/s41541-023-00687-x. NPJ Vaccines. 2023. PMID: 37277334 Free PMC article. No abstract available.
OVX033, a nucleocapsid-based vaccine candidate, provides broad-spectrum protection against SARS-CoV-2 variants in a hamster challenge model.
Primard C, Monchâtre-Leroy E, Del Campo J, Valsesia S, Nikly E, Chevandier M, Boué F, Servat A, Wasniewski M, Picard-Meyer E, Courant T, Collin N, Salguero FJ, Le Vert A, Guyon-Gellin D, Nicolas F. Primard C, et al. Among authors: collin n. Front Immunol. 2023 Jun 19;14:1188605. doi: 10.3389/fimmu.2023.1188605. eCollection 2023. Front Immunol. 2023. PMID: 37409116 Free PMC article.
Emulsion and liposome-based adjuvanted R21 vaccine formulations mediate protection against malaria through distinct immune mechanisms.
Reinke S, Pantazi E, Chappell GR, Sanchez-Martinez A, Guyon R, Fergusson JR, Salman AM, Aktar A, Mukhopadhyay E, Ventura RA, Auderset F, Dubois PM, Collin N, Hill AVS, Bezbradica JS, Milicic A. Reinke S, et al. Among authors: collin n. Cell Rep Med. 2023 Nov 21;4(11):101245. doi: 10.1016/j.xcrm.2023.101245. Epub 2023 Oct 31. Cell Rep Med. 2023. PMID: 37913775 Free PMC article.
Potential business model for a European vaccine R&D infrastructure and its estimated socio-economic impact.
Jungbluth S, Martin W, Slezak M, Depraetere H, Guzman CA, Ussi A, Morrow D, Van Heuverswyn F, Arnouts S, Carrondo MJT, Olesen O, Ottenhoff THM, Dockrell HM, Ho MM, Dobly A, Christensen D, Segalés J, Laurent F, Lantier F, Stockhofe-Zurwieden N, Morelli F, Langermans JAM, Verreck FAW, Le Grand R, Sloots A, Medaglini D, Lawrenz M, Collin N. Jungbluth S, et al. Among authors: collin n. F1000Res. 2023 Oct 24;12:1401. doi: 10.12688/f1000research.141399.1. eCollection 2023. F1000Res. 2023. PMID: 38298529 Free PMC article.
Designing Adjuvant Formulations to Promote Immunogenicity and Protective Efficacy of Leptospira Immunoglobulin-Like Protein A Subunit Vaccine.
Techawiwattanaboon T, Courant T, Brunner L, Sathean-Anan-Kun S, Krangvichian P, Iadsee N, Nakornpakdee Y, Sangjun N, Komanee P, Collin N, Ruxrungtham K, Patarakul K. Techawiwattanaboon T, et al. Among authors: collin n. Front Cell Infect Microbiol. 2022 Jun 16;12:918629. doi: 10.3389/fcimb.2022.918629. eCollection 2022. Front Cell Infect Microbiol. 2022. PMID: 35782116 Free PMC article.
65 results